Sterling Pharma Solutions commence the production of potential COVID-19 treatment

11th May 2020

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has commenced production of hydroxychloroquine (HCQ), a treatment currently under investigation for COVID-19.

Sterling will be manufacturing the active pharmaceutical ingredient (API) with the finished product being manufactured and supplied by Accord Healthcare.

The UK’s current supply of HCQ is sourced from overseas, primarily as a result of economic pressures driving production to lower cost manufacturing regions. This new deal with Accord will establish a domestic supply of the product ensuring access for patients in the UK, should the drug prove successful.

Kevin Cook CEO at Sterling Pharma Solutions said, “While it is currently unclear whether HCQ will be a viable treatment for COVID-19, it is vital to proactively establish a strong supply route ahead of time.

“Rapid response to a rapidly changing landscape has been key here. We have worked quickly alongside Accord Healthcare to establish a UK supply chain for this product.

“HCQ could potentially provide an effective treatment for COVID patients and during such an unprecedented time it’s important that the pharmaceutical industry works flexibly to achieve maximum results as quickly as possible and this partnership is a good example of that.”

Sterling has already supported Accord with the purchase of over 50 tonnes of the key raw materials, which equates to roughly 60 million finished tablets of HCQ.

As a result of the partnership Accord expects to supply up to 50 million HCQ tablets per month and has already started production of HCQ from its manufacturing facility in Barnstable, UK.

Related content


Sterling announces exclusive partnership with the University of Manchester to develop novel route to newly approved COVID-19 therapy, Molnupiravir


Sterling signs deal to produce potential COVID-19 drug candidate for Moleculin

API Manufacturing